Multiple autoantibody detection in esophageal cancerous or precancerous serum using tumor-associated antigens microarray / 肿瘤

ABSTRACT

Objective: To identify serum autoantibody biomarkers by an tumor-associated antigens (TAAs)-based microarray in the patients with esophageal precancerous lesions (EPLs) and patients with esophageal cancer (EC). Methods: The antigens microarray with 55 TAAs was used to detect the serum autoantibodies of the residency-, age-, and sex-matched 26 pairs, which included 26 cases with EC, 26 cases with EPLs and 26 normal controls. The cut-off value was defined as mean ± 2 standard deviation of the expression levels of the antibodies in the normal control group. The value corresponding to the expression level of the antibody beyond the range of cut-off value was considered seropositive. Results: Five autoantibodies (CYFRA21-1, CA72-4, NY-ESO-1, GAGE-7 and SCCA) were significantly up-regulated, and others were down-regulated. Twenty-five autoantibodies had significant difference among EC, EPLs and normal controls which were found by multi-factor analysis of variance. Serum antibodies could be detected by 9 antigens, including CA72-4, CCNB1, CDKN2A, NY-ESO-1, CYFRA21-1, E2F1, ERBB2, GAGE-7 and SCCA. The positive detection rates of CYFRA21-1 were the highest in EC and EPLs, which were 61.54% and 60.00%, respectively. Furthermore, other antigens with higher seropositive rates were NY-ESO-1 (50.00% for EC, 52.00% for EPLs), SCCA (46.15% for EC, 48.00% for EPLs), GAGE-7 (46.15% for EC, 24.00% for EPLs) and CA72-4 (34.62% for EC, 16.00% for EPLs) in turn. The seropositive rates of these 9 antigens in combined detection panel were 88.46% and 84.00% for EC and EPLs, respectively. Conclusion: CYFRA21-1 is possibly used as an autoantibody indicator for early screening of EC and EPLs. The combined detection of the 9 antigens is likely to improve the sensitivity of autoantibody detection in EC and EPLs serum samples. Copyright © 2013 by TUMOR.